A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

August 23, 2024

Study Completion Date

March 5, 2025

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Macitentan

Macitentan will be administered orally as a tablet.

Trial Locations (11)

399-8288

Nagano Children's Hospital, Azumino-shi

113 8519

Institute of Science Tokyo Hospital, Bunkyō City

813-0017

Fukuoka Children's Hospital, Fukuoka

700 8558

Okayama University Hospital, Okayama

143-8541

Toho University Medical Center Omori Hospital, Ōta-ku

060-8648

Hokkaido University Hospital, Sapporo

157 8535

National Center for Child Health and Development, Setagaya Ku

162-8666

Tokyo Women's Medical University Hospital, Shinjuku-ku

564-8565

National Cerebral and Cardiovascular Center, Suita-Shi

565-0871

Osaka University Hospital, Suita-shi

113-8655

The University of Tokyo Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT05167825 - A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter